Document Detail


The role of menopausal hormone therapy in preventing osteoporotic fractures: a critical review of the clinical evidence.
MedLine Citation:
PMID:  16227948     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Osteoporosis is a common disease resulting in millions of potentially preventable fractures each year. Women are disproportionately affected by osteoporosis compared to men, with loss of gonadal functioning and aging being the 2 most important contributing factors to osteoporosis. For many decades, menopausal hormone therapy (HT) has been the mainstay for the prevention and treatment of osteoporosis among menopausal women. While recent randomized trial data have confirmed findings from observational studies concerning HT's protective effect on osteoporosis, they showed that HT increases the risks of breast cancer, venous thromboses, stroke, and coronary heart disease. With a strong body of evidence showing the benefit of HT in preventing osteoporotic fractures, the challenge facing clinicians is not whether HT helps to prevent osteoporotic fractures, but whether HT's fracture-prevention benefits outweigh its risks. With several medications now available having efficacy comparable to HT in preventing fractures, decisions about therapy for osteoporosis or osteopenia should take into consideration bone mineral density, other risk factors for osteoporotic fracture, and a careful examination of the benefits and risks of each treatment option. After a brief discussion of the epidemiology and pathophysiology of osteoporosis, we review the evidence from observational studies and randomized studies examining the impact of menopausal hormone therapy on osteoporosis. We focus on whether there are specific subgroups of women that accrue greater or smaller benefit from HT in terms of osteoporotic fracture reduction. We then expand our perspective to include clinical endpoints other than osteoporosis, presenting a framework for factoring in the many risks and benefits of HT. We conclude that all women should be informed of all alternative treatment options and allowed to make an informed treatment decision according to their personal risks, preferences, values, and willingness to tolerate the risks of treatment.
Authors:
N F Col; L A Bowlby; K McGarry
Related Documents :
20360038 - Prevalence and risk factors of vertebral fractures in women with rheumatoid arthritis u...
22594728 - Menthol brand switching among adolescents and young adults in the national youth smokin...
12200648 - Is it necessary to screen for celiac disease in postmenopausal osteoporotic women?
19937228 - Urinary cadmium, osteopenia, and osteoporosis in the us population.
16223098 - Tobacco smoking and periodontal health in a saudi arabian population.
12814388 - Individuals at increased coronary heart disease risk are characterized by an impaired m...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Minerva medica     Volume:  96     ISSN:  0026-4806     ISO Abbreviation:  Minerva Med.     Publication Date:  2005 Oct 
Date Detail:
Created Date:  2005-10-17     Completed Date:  2005-12-28     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0400732     Medline TA:  Minerva Med     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  331-42     Citation Subset:  IM    
Affiliation:
Division of General Internal Medicine, Rhode Island Hospital, Brown University Medical School, Providence, RI 02903, USA. ncol@lifespan.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Bone Density
Bone Density Conservation Agents / therapeutic use
Estrogen Replacement Therapy*
Female
Fractures, Bone / prevention & control*
Fractures, Spontaneous / prevention & control*
Humans
Osteoporosis, Postmenopausal / complications,  physiopathology,  prevention & control*
Randomized Controlled Trials as Topic
Grant Support
ID/Acronym/Agency:
R01 HS013329-01/HS/AHRQ HHS
Chemical
Reg. No./Substance:
0/Bone Density Conservation Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Clinical applications of bone density testing for osteoporosis.
Next Document:  Prevention and treatment of osteoporotic fractures.